cas 319-03-9|| where to buy 5-Fluoroisobenzofuran-1,3-dione

Product Name:5-Fluoroisobenzofuran-1,3-dione

IUPAC Name:5-fluoro-1,3-dihydro-2-benzofuran-1,3-dione

Packing Unit	Available Stock	Price($)
CM308290-25g	in stock	ƩĜţ
CM308290-100g	in stock	Əţǭ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:319-03-9; Molecular Formula:C8H3FO3; Melting Point:-; Smiles Code:O=C1OC(C2=C1C=CC(F)=C2)=O; Density:

: Catalog Number:CM308290; Molecular Weight:166.11; Boiling Point:; MDL No:MFCD00191363; Storage:Keep in a dry and a tight container and store at ambient temperature

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.